PharmiNews

The Directory of Pharma Companies and News

Midatech Pharma

Midatech is a nanomedicine company focused on the development and commercialisation of multiple, high-value, targeted therapies for major diseases with unmet medical need. These diseases include diabetes, rare cancers including brain (glioblastoma), ovarian, liver and pancreatic cancer and neurological/ophthalmologic conditions. Midatech�s strategy is to develop its products in-house in rare cancers and with partners in other indications, and to accelerate growth of its business through strategic acquisition of complementary products and technologies. Midatech�s core product candidates derive from its two multi-applicable platform technologies that can be used alone or in combination to enable the targeted delivery (�right place�) and controlled release (�right time�) of existing drugs. These technologies are provided through its wholly-owned subsidiaries, Midatech and Q-Chip (acquired in 2014). Midatech�s core platform is a drug conjugate delivery system based on a patented form of gold nanoparticles (GNP) combined with existing drugs for the safe and targeted release of therapeutic payloads at specific organs, cells or sites of disease. The Group�s second platform is a sustained release technology acquired with Q Chip that involves the consistent and precise encapsulation of active drug compounds within polymer microspheres enabling their release into the body in a highly controlled manner over a prolonged period of time. On 4 June 2015, Midatech announced a proposed acquisition of DARA BioSciences, Inc. (NASDAQ: DARA), an oncology supportive care pharmaceutical company, based in Raleigh, NC. The acquisition brings a portfolio of marketed oncology products and a salesforce in US to Midatech and is expected to complete in H2 2015. The Group is headquartered near Oxford, UK, with a nanoparticle manufacturing operation in Bilbao, Spain and an R&D facility in Cardiff, UK.
Category:
Category:

Midatech Pharma News

DateNews
2016-07-07Grant funding received to explore Midatech’s gold nanoparticle technology in immunotherapy
2016-05-18Midatech Pharma announces clinical pipeline update
2016-05-11AGM Statement and Update on Trading
2016-04-26Midatech Pharma announces positive pharmacokinetic data with Q-Octreotide
2016-04-21Midatech achieves positive dosing data for OpsiSporin Uveitis programme
2016-04-13Audited financial results for the year ended 31 December 2015
2016-04-11Midatech’s Commercial Launch of Zuplenz® (Ondansetron) Oral Soluble Film to Prevent Post-Operative, Chemotherapy and Rad...
2016-02-29Midatech Pharma Recognises International Rare Disease Day 2016
2016-01-06Pre-close Trading Update
2016-01-04Midatech signs licencing agreement with Emergex Vaccines
2015-12-30Midatech completes acquisition of Zuplenz®
2015-12-18Midatech agrees to acquire marketed oncology product, Zuplenz®, from Galena Biopharma, Inc.
2015-12-14Midatech signs supply agreement with Centurion Pharma
2015-10-27Midatech selects Fujitsu to provide IT solutions
2015-08-13Ocular Agreement with Ophthotech
2015-07-20Initiation of Phase IIa study of insulin delivery via buccal strip for type 1 diabetes
2015-04-14Research Collaboration Signed with National Cancer Center for Targeted Nanomedicines against Glioblastoma
2015-02-18Midatech Pharma Appoints Katharine Andrews as Head of Regulatory Affairs
2015-02-09Midatech Pharma Wins Innovation & Excellence in Healthcare Award
2015-01-20Midatech Biogune completes the refit to adapt to aseptic manufacture
2014-12-17Midatech Pharma awarded EU grant funding to support training and research into glycan based multivalent immunotherapeuti...
2014-12-08Midatech Pharma acquires Q Chip to support novel delivery platforms and product developments in cancer, diabetes and oph...
2014-12-08Admission and First Day of Dealings on AIM following £32 million Placing and Completion of Acquisition of Q Chip
2014-11-20Midatech Pharma-led consortium selected for €7.9 million EU grant funding
2014-09-10Midatech Biogune receives financial support from the Spanish Government:
2014-07-02Midatech appoints Nick Robbins-Cherry as Finance Director
2014-06-20Midatech forms distinguished Neuro-Oncology Advisory Board
2014-06-18Positive Results from Phase I Clinical Study with MidaForm Insulin PharmaFilm® Presented at the American Diabetes Associ...
2014-05-12Midatech forms prestigious Scientific Advisory Board
2014-05-06Midatech wins grant funding from Spanish government
2014-04-30Midatech appoints Rolf Stahel as Chairman
Brought to you by PharmiWeb.com - Latest Jobs in Pharma
Brought to you by www.pharmiweb.com - Latest Jobs in Pharma.